Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas
Intratumoral ulevostinag (±pembrolizumab) had manageable toxicity, dose-dependent pharmacokinetics, and evidence of STING activation and target engagement. Combination therapy showed antitumor activity in participants with untreated metastatic or unresectable, recurrent HNSCC.
Authors
- Carlos Gomez‐Roca (ORCID: https://orcid.org/0000-0002-8043-2529)
- John Hyngstrom (ORCID: https://orcid.org/0000-0002-4833-3838)
- Thomas Jemielita (ORCID: https://orcid.org/0000-0001-7788-1828)
- Joshua Brody (ORCID: https://orcid.org/0000-0002-0850-6730)
- Aron Popovtzer (ORCID: https://orcid.org/0000-0003-4428-9232)
- Sung‐Bae Kim (ORCID: https://orcid.org/0000-0001-5588-8332)
- James Strauss (ORCID: https://orcid.org/0000-0001-6414-6998)
- Matthew Ingham (ORCID: https://orcid.org/0000-0002-5518-8413)
- Ruth Perets (ORCID: https://orcid.org/0000-0001-7216-6577)
- Deborah J. L. Wong (ORCID: https://orcid.org/0000-0002-7811-7247)
- David Yoonsuk Oh (ORCID: https://orcid.org/0000-0002-3310-0994)
- Stéphane Champiat (ORCID: https://orcid.org/0000-0002-0741-2118)
- Anuradha Khilnani
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Kevin Joseph Harrington (ORCID: https://orcid.org/0000-0002-6014-348X)
- Steven Powell (ORCID: https://orcid.org/0000-0002-5029-0048)
- Runchen Zhao (ORCID: https://orcid.org/0000-0001-8673-3990)
- Talia Golan (ORCID: https://orcid.org/0000-0001-5939-7012)
- Emanuela Romano (ORCID: https://orcid.org/0000-0002-1574-5545)
- Qing Zhao
Institutions
- Ulsan College (KR)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Institute of Cancer Research (GB)
- Inserm (FR)
- University of California, Los Angeles (US)
- Tel Aviv University (IL)
- Technion – Israel Institute of Technology (IL)
- University of California, San Francisco (US)
- Yonsei University (KR)
- Université Paris Sciences et Lettres (FR)
- Columbia University Irving Medical Center (US)
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Huntsman Cancer Institute (US)
- Rambam Health Care Campus (IL)
- Asan Medical Center (KR)
- Institut Gustave Roussy (FR)
- University of Ulsan (KR)
- Mary Crowley Cancer Research Center (US)
- Sanford Research (US)
- Immunité et Cancer (FR)
- EMD Serono, Inc. (United States) (US)
- Merck Institute for Science Education (US)
- Institut Claudius Regaud (FR)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Institut Curie (FR)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3630
- Citations
- 23
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 18.34